Dermotic Oil
NDC Package 68791-103-20
Package Information
Dermotic (fluocinolone acetonide) oils is a medication used to treat eczema of the outer ear (also known as chronic itchy ear). This formulation utilizes a oil delivery system. Marketed by Royal Pharmaceuticals, this product is identified by NDC 68791-103 and is authorized under FDA application NDA019452.
Identification & Billing
- RxCUI: 1191299 - fluocinolone acetonide 0.01 % Oil for Otic Solution
- RxCUI: 1191299 - fluocinolone acetonide 0.1 MG/ML Otic Solution
- RxCUI: 1191299 - fluocinolone acetonide 0.01 % Auricular Oil
- RxCUI: 1191301 - DermOtic Oil 0.01 % Otic Solution
- RxCUI: 1191301 - fluocinolone acetonide 0.1 MG/ML Otic Solution [Dermotic]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68791 - Royal Pharmaceuticals
- 68791-103 - Dermotic
- 68791-103-20 - 1 BOTTLE, DROPPER in 1 CARTON / 20 mL in 1 BOTTLE, DROPPER
- 68791-103 - Dermotic
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68791-103-20 identifies a specific commercial package of 1 bottle, dropper in 1 carton / 20 ml in 1 bottle, dropper of Dermotic, a human prescription drug labeled by Royal Pharmaceuticals. This oil is formulated for auricular (otic) use and contains fluocinolone acetonide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Royal Pharmaceuticals on November 09, 2005. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat eczema of the outer ear (also known as chronic itchy ear). The main symptom is itchiness, but redness, flaking, or oozing may also occur. Fluocinolone reduces these symptoms. This medication is a low- to medium-strength corticosteroid.
How is this Royal Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68791010320. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.